CG Oncology, Inc.
CGON
$63.57
-$0.88-1.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.04M | 2.17M | 551.00K | 662.00K | 1.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.04M | 2.17M | 551.00K | 662.00K | 1.14M |
| Cost of Revenue | 121.29M | 115.06M | 105.22M | 92.36M | 82.10M |
| Gross Profit | -117.25M | -112.89M | -104.67M | -91.70M | -80.96M |
| SG&A Expenses | 73.53M | 67.24M | 52.62M | 42.70M | 33.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 194.81M | 182.30M | 157.84M | 135.06M | 115.81M |
| Operating Income | -190.77M | -180.12M | -157.29M | -134.40M | -114.67M |
| Income Before Tax | -161.00M | -151.48M | -128.08M | -105.56M | -88.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -161.00 | -151.48 | -128.08 | -105.56 | -88.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -161.00M | -151.48M | -128.08M | -105.56M | -88.04M |
| EBIT | -190.77M | -180.12M | -157.29M | -134.40M | -114.67M |
| EBITDA | -189.33M | -179.53M | -157.09M | -134.35M | -114.63M |
| EPS Basic | -2.08 | -2.03 | -1.76 | -1.50 | -1.41 |
| Normalized Basic EPS | -1.30 | -1.27 | -1.10 | -0.94 | -0.88 |
| EPS Diluted | -2.08 | -2.03 | -1.76 | -1.50 | -1.41 |
| Normalized Diluted EPS | -1.30 | -1.27 | -1.10 | -0.94 | -0.88 |
| Average Basic Shares Outstanding | 309.21M | 298.20M | 288.61M | 279.03M | 249.91M |
| Average Diluted Shares Outstanding | 309.21M | 298.20M | 288.61M | 279.03M | 249.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |